Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Effects of human umbilical cord mesenchymal stem cells derived from exosomes on migration ability of endometrial glandular epithelial cells

Feng Y., Zhan F., Zhong Y., Tan B.

Prospective Study on Chronic Wound, published in Mol Med Rep (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Mol Med Rep (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32626977
PMCID
PMC7339775
DOI
10.3892/mmr.2020.11137
Citations
17

Abstract (original English)

The present study aimed to investigate the effects of human umbilical cord mesenchymal stem cells (Huc‑MSCs)‑derived exosomes on the migratory abilities of endometrial glandular epithelial cells, and to evaluate the underlying mechanism from the perspective of epithelial‑mesenchymal transition (EMT). Huc‑MSCs were prepared from human umbilical cord, and eutopic endometrial glandular epithelial cells were isolated from patients with endometriosis. The exosomes derived from Huc‑MSCs (Huc‑MSCs‑exo) were prepared using an exosome extraction kit. The endometrial glandular epithelial cells were randomly divided into two groups: Huc‑MSCs‑exo and control. Cell migratory ability was assessed and western blotting was used to detect the expression levels of EMT. The results of the present study demonstrated that Huc‑MSCs‑exo treatment significantly enhanced the migration of endometrial glandular epithelial cells from patients with endometriosis (P<0.05). The present study also demonstrated that treatment with Huc‑MSCs‑exo inhibited the expression levels of E‑cadherin and promoted the expression levels of Vimentin and N‑cadherin at both the mRNA and protein level. The results of the current study indicate that Huc‑MSCs‑exo enhance the migratory ability of endometrial glandular epithelial cells via promotion of EMT.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
EndometriumCells, CulturedEpithelial CellsMesenchymal Stem CellsUmbilical CordHumansEndometriosisVimentinCadherinsAntigens, CD

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research